CSRxP Statement on CMS Changes to Medicare Part B
Aug 7, 2018
CSRxP spokesman Will Holley released the following statement following… Read More
© 2024 CSRXP- All Rights Reserved
Statements
New Report Demonstrates Big Pharma’s Abuses of the Patent System
Aug 2, 2018
CSRxP spokesman Will Holley released the following statement on the release of… Read More
High Priced Drugs Lead to Banner Q2 Earnings for Big Pharma
Jul 27, 2018
CSRxP released the following statement following a week of strong Q2 earnings… Read More
CSRxP on Lilly & Biogen Earnings
Jul 24, 2018
CSRxP released the following statement following the release of Eli Lilly and… Read More
CSRxP Applauds Admin Focus on Drug Prices
Jul 19, 2018
CSRxP spokesman Will Holley released the following statement applauding the… Read More
CSRxP Applauds FDA’s Biosimilars Action Plan
Jul 18, 2018
“We applaud Commissioner Gottlieb and the FDA for their leadership on… Read More
CSRxP Releases Comments on Drug Price Blueprint
Jul 13, 2018
The Department of Health and Human Services is taking a good first step in the… Read More
CSRxP Statement on Novartis’ $475,000 Price Tag for Kymriah
Aug 30, 2017
"While we are very excited about the potential for CAR-T therapies to save lives, Novartis’ pricing decision disappointingly pushes an unsustainable trend even closer to the breaking point." Read More
CSRxP Calls for Action on CREATES Act
Jul 27, 2017
CSRxP Calls for Action on CREATES Act The Campaign for Sustainable Rx Pricing… Read More
CSRxP Releases Powerful Testimonial: “Debbie’s Story”
Jul 10, 2017
CSRxP Releases Powerful Testimonial: “Debbie’s Story” The… Read More
CSRxP Applauds Introduction of the CREATES Act
Apr 27, 2017
“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety." Read More
Analysis Shows New Cholesterol Medications Are Not Cost Effective
Aug 16, 2016
"The dangerous trend of high-priced drugs has to be reversed and a common-sense solution like measuring the value and cost-effectiveness of medications is one necessary step to fix the broken prescription drug market, but it must also be combined with increased transparency and competition.” Read More